Welireg™ (belzutifan) – New drug approval
August 13, 2021 - The FDA announced the approval of Merck’s Welireg (belzutifan), for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Top